Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 4/20 | 0.44 |
| ▸ | PDE3A | Q14432 | 4/20 | 0.44 |
| ▸ | GRIN1 | Q05586 | 6/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 6/20 | 0.44 |
| ▸ | TRPA1 | O75762 | 4/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.43 |
| ▸ | MPL | P40238 | 2/20 | 0.41 |
| ▸ | KMO | O15229 | 2/20 | 0.41 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1722753 | 0.78 | KIF11 (0.46) | PIK3CA | |
| SCHEMBL31030963 | 0.76 | MPL (0.55) | PDE3BPDE3AMPLKMO | |
| SCHEMBL29901554 | 0.75 | GRIN2B (0.52) | GRIN1GRIN2BTRPA1PIK3CATRPM8 | |
| SCHEMBL1691424 | 0.75 | HTR3A (0.45) | TRPA1PIK3CA | |
| SCHEMBL10536966 | 0.74 | IDO1 (0.51) | GRIN1GRIN2B | |
| SCHEMBL1769907 | 0.73 | KDR (0.50) | PDE3BPDE3AMPLKMO | |
| SCHEMBL4718970 | 0.73 | FEN1 (0.46) | TRPA1PIK3CAMPL | |
| SCHEMBL10537216 | 0.72 | AOC3 (0.50) | PIK3CA | |
| SCHEMBL28513983 | 0.72 | AXL (0.45) | — | |
| SCHEMBL27750225 | 0.71 | PDE3B (0.43) | PDE3BPDE3AGRIN1GRIN2BTRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1532120-B1 | PHENYLPYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME (GB) | 2009-01-14 | — | — | EP | disclosed |
| US-20060235021-A1 | Phenylpyridazine derivatives as ligands for gaba receptors | MERCK SHARP & DOHME LTD. (GB) | 2006-10-19 | — | — | US | disclosed |
| EP-1532120-A1 | PHENYLPYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LTD. (GB) | 2005-05-25 | — | — | EP | disclosed |
| WO-2004014865-A1 | PHENYLPYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LIMITED (GB) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060235021-A1 | Phenylpyridazine derivatives as ligands for gaba receptors | GABRA5, GABRA2, GABRA3 | PDE3B 507/4885PDE3A 472/4885GRIN1 89/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.